Skye Bioscience, Inc. (SKYE) - Dilution Analysis

10-Q filing | 35.1M shares outstanding

10-K filing | 33.4M shares outstanding

10-Q filing | 32.1M shares outstanding

10-Q filing | 31.0M shares outstanding

10-Q filing | 31.0M shares outstanding

10-K filing | 31.0M shares outstanding

10-Q filing | 30.3M shares outstanding

10-Q filing | 30.3M shares outstanding

S-3 filing: This is an S-3 filing for a shelf offering of up to 4,000,000 shares of common stock for resale by selling securityholders.

S-3 filing: This is an S-3 filing for an at-the-market offering of common stock with an aggregate offering price of up to $100,000,000.

10-Q filing | 28.0M shares outstanding

POS AM filing: This POS AM filing relates to the offering of up to 33,753,271 shares of common stock by selling securityholders.

S-1 filing: This prospectus relates to the possible resale from time to time by the selling securityholders named herein of up to 33,753,271 shares of common stock, $0.001 par value per share.

10-K filing | 28.1M shares outstanding

8-K filing: Skye Bioscience, Inc. completed a private placement, issuing and selling 4,000,000 shares of common stock at a price of $10.00 per share, resulting in gross proceeds of $40,000,000 before deducting fees and expenses. ($40.0M proceeds)

8-K filing: Skye Bioscience, Inc. entered into a Securities Purchase Agreement with institutional investors to issue and sell 11,822,124 shares of common stock at $2.305 per share and pre-funded warrants to purchase up to 9,978,739 shares of common stock at $2.3049 per pre-funded warrant, with expected gross proceeds of $50,249,991. ($50.25M proceeds)

10-Q filing | 12.3M shares outstanding

8-K filing: Stock split 1-for-250 | Outstanding: 3,080,000,000 → 12,312,551

8-K filing: Skye Bioscience, Inc. completed the acquisition of Bird Rock Bio, Inc. and issued shares of common stock in connection with the merger and a private placement. ($12.0M proceeds)

10-Q filing | 971.5M shares outstanding

10-Q filing | 941.9M shares outstanding

10-K filing | 971.5M shares outstanding

8-K filing: Skye Bioscience, Inc. issued 16,641,486 shares of common stock to Emerald Health Sciences, Inc. upon warrant exercise and 41,379,164 shares of common stock upon conversion of debt. ($1.88M proceeds)

10-Q filing | 912.2M shares outstanding

10-Q filing | 495.9M shares outstanding

10-Q filing | 495.8M shares outstanding

10-K filing | 495.9M shares outstanding

10-Q filing | 476.1M shares outstanding

8-K filing: Skye Bioscience, Inc. entered into a securities purchase agreement for a registered direct offering involving the sale of common stock, pre-funded warrants, and warrants, expecting to receive gross proceeds of approximately $7.0 million. ($7.0M proceeds)

10-Q filing | 378.4M shares outstanding

S-3 filing: SKYE Bioscience, Inc. is offering a combination of common stock and preferred stock with an aggregate amount of $75,000,000.

8-K filing: Skye Bioscience, Inc. entered into a letter agreement with accredited investors to exercise warrants to purchase 21,166,667 shares of common stock at $0.06 per share, with gross proceeds expected to be approximately $1.27 million. ($1.27M proceeds)

10-Q filing | 336.9M shares outstanding

10-K filing | 350.0M shares outstanding

10-Q filing | 256.8M shares outstanding

10-Q filing | 239.5M shares outstanding

8-K filing: Emerald Bioscience, Inc. closed an offering on August 4, 2020, issuing units consisting of common stock and warrants at $0.06 per Common Unit and pre-funded warrants and warrants at $0.059 per Pre-Funded Unit, raising gross proceeds of approximately $7.0 million. ($21.0M proceeds)

S-1/A filing: The company is offering common units, pre-funded units, and warrants to purchase common stock, with the intention to use the net proceeds for general corporate purposes, including working capital and possible acquisitions.

10-Q filing | 183.7M shares outstanding

8-K filing: Emerald Bioscience, Inc. entered into an Amended and Restated Multi-Draw Credit Agreement with Emerald Health Sciences, Inc. for a credit facility of up to $20,000,000, including warrants to purchase 7,500,000 shares of common stock at $0.50 per share; the Lender exercised 40,800,000 warrants and paid $4,080,000. ($4.08M proceeds)

10-K filing | 169.6M shares outstanding